Uflex Q1FY27 revenue rises 38% to ₹54,000 crore; management guides 35% FY27 growth
- Revenue rose 38% YoY to ₹53,972 million; normalized PAT surged 630% to ₹4,233 million
- EBITDA margin expanded 480 bps to 17.0%, driven by overseas operations and price pass-throughs
- Management guides for 35% YoY growth in top-line and EBITDA for FY27
- Debt-to-EBITDA multiple improved to 3.5x from 4.5x; net debt stands at ₹85,875 million
- Egypt aseptic plant and Mexico WPP facility commissioned; 60-70% future capex targeted at value-added products
*this image is generated using AI for illustrative purposes only.
Uflex Limited reported consolidated revenue of ₹53,972 million for Q1FY27, a 38% year-on-year increase. Normalized profit after tax (PAT) surged to ₹4,233 million, up 630% from the prior year period, driven by strong overseas performance and operational leverage.
The Board of Directors approved the financial results during a meeting held on August 14, 2026. Management provided guidance for FY27, expecting at least 35% growth in both top-line revenue and EBITDA compared to FY26. The company also highlighted that its debt-to-EBITDA multiple has improved to 3.5x from 4.5x in FY26.
Financial Performance
Revenue from operations stood at ₹53,660 million, while total income reached ₹53,972 million. EBITDA expanded by 92.1% year-on-year to ₹9,198 million, with margins widening to 17.0% from 12.2% in Q1FY26. This margin expansion was primarily driven by overseas businesses, particularly in Egypt, Mexico, and Poland, alongside the India PET chips business.
Normalized EBITDA, which excludes foreign currency fluctuations and derivative gains/losses, grew 78.2% year-on-year to ₹8,373 million, with margins improving to 15.5%. The company recorded a forex gain and derivative income of ₹825 million in the quarter. Consolidated net margin stood at 7.8%, compared to 1.5% in Q1FY26.
| Metric | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Total Income | ₹53,972 million | ₹39,219 million | +37.6% |
| EBITDA | ₹9,198 million | ₹4,788 million | +92.1% |
| EBITDA Margin | 17.0% | 12.2% | +480 bps |
| Normalized EBITDA | ₹8,373 million | ₹4,698 million | +78.2% |
| Normalized PAT | ₹4,233 million | ₹580 million | +629.6% |
Operational Highlights
Sales volumes increased by 1.7% year-on-year to 173,471 metric tons. Packaging films volumes grew 4.9% year-on-year, contributing 78.5% of total sales volume. In contrast, packaging volumes declined 8.4% year-on-year due to softer aseptic volumes amid aggressive pricing from duty-free imports domestically and supply disruptions overseas linked to the West Asia crisis.
Virgin PET chips third-party sales volumes rose 31.4% quarter-on-quarter to 29,471 metric tons, led by a 41.0% sequential growth in India. Price realizations for BOPP and BOPET films increased by 25-35% from February 2026 levels, supported by localized sourcing premiums and supply chain derisking by customers.
Capital Expenditure and Capacity
Uflex incurred capital expenditure of ₹4,782 million in Q1FY27. Key projects included the Egypt aseptic facility (₹1,236 million), Mexico WPP bags facility (₹205 million), Noida recycling unit (₹320 million), and Dharwad BOPP line (₹215 million).
The company commissioned its 39,600 MTPA recycling facility in Noida on April 30, 2026, and the 80-million-unit WPP bags facility in Mexico on July 31, 2026. Net debt stood at ₹85,875 million as of June 30, 2026, compared to ₹73,055 million in Q1FY26. Management indicated that approximately 60-70% of future capex will be allocated to value-added products.
What the Numbers Show
Overseas operations contributed 91% of the incremental EBITDA of ₹4,410 million, highlighting the company's shift toward higher-margin international markets. With 80% of incremental revenue coming from overseas, Uflex is effectively leveraging its global footprint to offset domestic pricing pressures. The significant rise in PAT margins from 1.5% to 7.8% reflects not only operational leverage but also optimized tax expenses from profits generated in jurisdictions with favorable tax brackets.
Market Context
Domestically, India’s consumption environment showed signs of recovery with resilient FMCG volume growth. Globally, demand for packaging films remained strong in the Americas and Middle East & Africa regions, driven by local sourcing trends amid geopolitical tensions in West Asia which disrupted raw material transit routes and elevated freight costs. Management expects these dynamics to support sustained volume growth, with total volumes potentially doubling by FY29.
Historical Stock Returns for UFLEX
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.27% | +6.79% | +42.52% | +50.59% | +22.82% | 0.0% |
How sustainable is the 17.0% EBITDA margin given the potential normalization of forex gains and the easing of supply chain disruptions in West Asia?
What specific strategies will Uflex employ to mitigate the impact of aggressive pricing from duty-free imports on its domestic aseptic packaging volumes?
Will the allocation of 60-70% of future capex to value-added products significantly alter the company's revenue mix and margin profile by FY29?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
